Enliven Therapeutics, Inc. ELVN
44.94 USD -2.31 (-4.90%)
Nov 5, 2026, 3:30 PM EST
43.93 Day range 47.73
14.79 52-week range 62.32
- YTD
- +191.80%
- 1 year
- +142.90%
Analyst view
Price target (mean) 74.42 +65.6% upside
Now 44.94
- Target (low)
- 69.00
- Target (mean)
- 74.42
- Target (high)
- 82.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.4522 | -0.52 – -0.38 | -0.32 | -41.3% | 0 | 0.0% | 8 |
| Next quarter | -0.5527 | -0.69 – -0.46 | -0.48 | -15.2% | 0 | 0.0% | 8 |
| Current year | -1.91 | -2.55 – -1.38 | -1.83 | -4.6% | 0 | 0.0% | 8 |
| Next year | -2.32 | -2.60 – -1.94 | -1.91 | -21.1% | 5.00K | 0.0% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 2, 2026 | Morgan Stanley | Initiated | — | Overweight |
| Oct 1, 2026 | JP Morgan | Initiated | — | Overweight |
| Aug 18, 2026 | William Blair | Initiated | — | Outperform |
| Aug 18, 2026 | Barclays | Initiated | — | Overweight |
| Aug 18, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 21, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 1, 2026 | Stifel | Maintained | Buy | Buy |
| Jun 29, 2026 | Jones Trading | Maintained | Buy | Buy |
| Jun 9, 2026 | Stifel | Initiated | — | Buy |
| Jun 2, 2026 | Mizuho | Maintained | Outperform | Outperform |
| May 8, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 16, 2025 | Goldman Sachs | Initiated | — | Buy |
| Jun 16, 2025 | Baird | Maintained | Outperform | Outperform |
| May 16, 2025 | Jones Trading | Maintained | Buy | Buy |
| May 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 13, 2024 | BTIG | Initiated | — | Buy |
| Nov 15, 2024 | Baird | Maintained | Outperform | Outperform |
| Oct 31, 2024 | Jones Trading | Initiated | — | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 9, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 11, 2024 | Baird | Initiated | — | Outperform |